Ascidian Therapeutics Join Hands with Roche to Discover and Develop RNA Exon Editing Therapies for Neurological Diseases
Shots:
- Ascidian Therapeutics and Roche have signed a research collaboration and licensing agreement to discover and develop RNA exon editing therapies for neurological disorders under which Roche gains exclusive rights to Ascidian’s RNA exon editing technology for undisclosed targets
- Ascidian, with Roche, will handle discovery & specific preclinical activities while Roche will oversee further preclinical & clinical development, manufacturing plus commercialization
- The agreement offers Ascidian an initial $42M and an additional $1.8B research, clinical & commercial milestones plus global sales-based royalties. Ascidian is free to develop other neurological targets independently or in partnership
Ref: Ipsen | Image: Ipsen
Related News:- Ipsen Enters into an Option Agreement with Skyhawk Therapeutics for Two RNA Targeting Small Molecules in Rare Neurological Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
